Clinical Nephrology, Volume 105 (2026) - February (92 - 96)

Magnesium in chronic hemodialysis

Marija Milinkovic1, 2, Lara Hadzi Tanovic1, Aleksandra Jovanovic1, Ivona Krivokapic1, Milija Bjelicic1, Marina Spasic1, Zoran Marjanović1, Mirjana Lausevic1, 2, Milica Kravljaca1, 2, Voin Brkovic1, 2, Milan Radovic1, 2, Dijana Jovanovic1, 2
1 Clinic for Nephrology, University Clinical Center of Serbia, and 2 Faculty of Medicine, University of Belgrade, Belgrade, Serbia

   

 

DOI 10.5414/CN111705

Abstract

Introduction and aim: Patients treated with hemodialysis (HD) are at increased risk for all-cause and cardiovascular (CV) mortality even after adjustments for traditional CV risk factors. The authors identified lower plasma magnesium (pMg) as a risk factor for arrhythmias and sudden death in people treated with HD. The aim of this study was to determine the connection between dialysate Mg concentrations (dMg) and the clinical characteristics of patients on chronic HD.
Materials and methods: An observational study including 103 chronic HD patients. Patients were divided into two groups based on dMg: group 1 (dMg = 0.5 mmol/L) and group 2 (dMg = 1 mmol/L). Variables were collected from patients’ medical documentation.
Results: There was no statistically significant difference between the groups regarding mean age (58.7 ± 14.6 vs. 58.9 ± 14.3 years, p = 0.972), HD duration (4 ± 0.3 vs. 4 ± 0.5 h, p = 0.849), mean Qb (283.3 ± 22.8 vs. 285.7 ± 21.9 mL/min, p = 0.597), mean Kt/V (1.53 ± 0.38 vs. 1.62 ± 0.35, p = 0.262) and mean dCa (1.61 ± 0.19 vs. 1.61 ± 0.16 mmol/L, p = 0.793). We found pMg concentration to be statistically significantly lower and intact parathyroid hormone (iPTH), to be statistically significantly higher in the low dMg group: 0.97 ± 0.73 vs. 1.31 ± 0.25 mmol/L, p = 0.007 and 242 (127 – 487) vs. 108 (47 – 290.75), p < 0.001, respectively. Mean QT interval did not differ significantly between the groups (380.7 ± 46.3 vs. 387.7 ± 50.3 ms, p = 0.488).
Conclusion: Higher dMg significantly increased pMg concentrations without significantly impacting the QT interval. This way we could safely increase pMg concentrations while potentially providing benefits regarding the control of secondary hyperparathyroidism.

Author Details

Authors

Departments

  • 1 Clinic for Nephrology, University Clinical Center of Serbia, and
  • 2 Faculty of Medicine, University of Belgrade, Belgrade, Serbia

Address

Marija Milinković, MD
Pasterova 2
11000 Belgrad, Serbia
Email: [email protected]

Citation

Marija Milinkovic, Lara Hadzi Tanovic, Aleksandra Jovanovic, Ivona Krivokapic, Milija Bjelicic, Marina Spasic, Zoran Marjanović, Mirjana Lausevic, Milica Kravljaca, Voin Brkovic, Milan Radovic, Dijana Jovanovic.Magnesium in chronic hemodialysis
. Clin Nephrol. 2026; 105: 92-96. doi: 10.5414/CN111705. Pubmed: https://pubmed.ncbi.nlm.nih.gov/41263307/; PMID: 41263307.

###article_not_exists_msg###

Shopping Overview

Shopping Overview
Type Qtty Discount VAT Price
Your basket is empty
View Cart